Price Reductions for Main, First Transitional and Second Transitional Cycles
Summary of 1 April 2012 Price Reductions for Main, First Transitional and Second Transitional Cycles by Drug / Manner of Administration / Weighted Average Percentage reduction
Drugs and Manner of Administration in the Main Cycle with a Weighted Average Percentage Reduction with a scheduled Reduction day of 1 April 2012
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Alprazolam |
Oral |
17.10% |
|
Amiodarone |
Oral |
18.89% |
|
Amlodipine |
Oral |
48.29% |
|
Amoxycillin |
Oral |
35.24% |
|
Amoxycillin with Clavulanic Acid |
Oral |
32.93% |
|
Atenolol |
Oral |
22.13% |
|
Azathioprine |
Oral |
14.15% |
|
Baclofen |
Oral |
31.05% |
|
Calcitriol |
Oral |
12.54% |
|
Captopril |
Oral |
15.33% |
|
Carboplatin |
Injection |
66.41% |
|
Cefaclor |
Oral |
20.38% |
|
Cephalexin |
Oral |
35.00% |
|
Ciprofloxacin |
Oral |
42.81% |
|
Citalopram |
Oral |
55.16% |
|
Clarithromycin |
Oral |
19.39% |
|
Clomipramine |
Oral |
12.32% |
|
Clozapine |
Oral |
26.23% |
|
Codeine with Paracetamol |
Oral |
32.27% |
|
Diltiazem |
Oral |
16.04% |
|
Enalapril |
Oral |
30.02% |
|
Epirubicin |
Injection/intravesical |
78.05% |
|
Famotidine |
Oral |
25.26% |
|
Felodipine |
Oral |
14.39% |
|
Flucloxacillin |
Injection |
26.65% |
|
Fluoxetine |
Oral |
18.67% |
|
Fluvoxamine |
Oral |
18.18% |
|
Frusemide |
Injection |
16.85% |
|
Gabapentin |
Oral |
28.83% |
|
Galantamine |
Oral |
17.55% |
|
Gemfibrozil |
Oral |
29.38% |
|
Glimepiride |
Oral |
26.69% |
|
Hydroxocobalamin |
Injection |
10.92% |
|
Isosorbide Mononitrate |
Oral |
10.45% |
|
Isotretinoin |
Oral |
13.69% |
|
Lactulose |
Oral |
24.69% |
|
Lamotrigine |
Oral |
20.93% |
|
Lansoprazole |
Oral |
20.92% |
|
Lercanidipine |
Oral |
24.36% |
|
Lisinopril |
Oral |
25.41% |
|
Metformin |
Oral |
17.16% |
|
Methotrexate |
Injection |
20.20% |
|
Metoprolol |
Oral |
18.81% |
|
Mirtazapine |
Oral |
25.55% |
|
Moclobemide |
Oral |
19.15% |
|
Nifedipine |
Oral |
15.74% |
|
Norfloxacin |
Oral |
31.92% |
|
Omeprazole |
Oral |
37.46% |
|
Omeprazole and Clarithromycin and Amoxycillin |
Oral |
11.93% |
|
Pantoprazole |
Oral |
37.97% |
|
Paroxetine |
Oral |
41.01% |
|
Perindopril |
Oral |
15.27% |
|
Pravastatin |
Oral |
49.94% |
|
Quinapril |
Oral |
24.30% |
|
Ramipril |
Oral |
37.54% |
|
Roxithromycin |
Oral |
34.22% |
|
Sertraline |
Oral |
45.26% |
|
Simvastatin |
Oral |
55.60% |
|
Sodium Chloride |
Injection/solvent for injectables |
82.71% |
|
Sotalol |
Oral |
28.71% |
|
Temazepam |
Oral |
15.34% |
|
Terbinafine |
Oral |
31.46% |
|
Ticlopidine |
Oral |
12.36% |
|
Tramadol |
Injection |
10.73% |
|
Tramadol |
Oral |
24.43% |
|
Trandolapril |
Oral |
20.53% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI) at the following link:
http://www.comlaw.gov.au/Details/F2011L02702
Drugs and Manner of Administration in the first Transitional Cycle with a Weighted Average Percentage Reduction with a scheduled Reduction day of 1 April 2012
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Alendronic Acid |
Oral |
31.84% |
|
Cisplatin |
Injection |
30.37% |
|
Fluconazole |
Oral |
15.00% |
|
Topiramate |
Oral |
11.62% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI) at the following link:
http://www.comlaw.gov.au/Details/F2011L02703
Drugs and Manner of Administration in the Second Transitional Cycle with a Weighted Average Percentage Reduction with a scheduled Reduction day of 1 April 2012
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Carvedilol |
Oral |
20.37% |
|
Clopidogrel |
Oral |
32.62% |
|
Gemcitabine |
Injection |
53.65% |
|
Irinotecan |
Injection |
64.63% |
|
Vinorelbine |
Injection |
63.87% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI) at the following link:
http://www.comlaw.gov.au/Details/F2011L02688
